Supreme Court Temporarily Preserves Telehealth Access to Abortion Pill Mifepristone Nationwide
Primary region US
Tags Justice · Health · Policy
Regions US
The US Supreme Court issued an administrative stay on May 5, 2026 blocking a 5th Circuit Court of Appeals ruling that had eliminated telehealth prescriptions and mail delivery of mifepristone nationwide. The stay preserves access at least while the Court considers emergency appeals. The 5th Circuit ruling would have reinstated the in-person dispensing requirement even in states where abortion is legal. Telehealth abortion now accounts for approximately 25% of all abortions in the United States. The Trump administration's FDA did not file a brief defending the 2023 Biden-era rule by the deadline. Nearly two dozen Democratic-led states filed an amicus brief arguing the appeals court decision improperly subordinated their sovereign policy choices to those of restrictive states.
Strategic interpretation
The Trump administration's non-defense of the FDA rule creates a politically difficult position: anti-abortion activists want stronger action while independent voters favor abortion rights ahead of the midterms. The White House meeting with anti-abortion activists on May 8 appears to be an effort to manage intra-party criticism. The Supreme Court's eventual ruling could have significant implications for both abortion access and the broader question of federal agency authority versus state regulatory power. The case also tests the Court's post-Dobbs framework for evaluating abortion-related regulations.